Human muscle tissues involve striated and smooth muscles. Each
muscle tissue possesses its own special function. Differences of
physiology functions among the
muscle tissues are mainly determined by their various
initiation and
signal transmission systems, defined as the pre-
muscle molecular motor mechanism, or initiating and regulating mechanism. The current medications, drugs, and therapies for diseases and symptoms related abnormal increased
muscle tone or excessive
muscle contraction are aimed just at the pre-muscle
molecular motor mechanisms, whereas without directly intending to effect on the muscle
molecular motor mechanism i.e. the contractile apparatus mechanism at all, which, however, is in common for all kinds of muscle tissues. The muscle molecular motor mechanism mainly involves recycling of
actin-
myosin filament cross-bridge formation and sliding movement. In the process, bio-energy provided by ATP
hydrolysis is necessarily required. Therefore, abnormal increased
muscle tone or excessive contraction of muscle tissues under diseased conditions may be modified by inhibition of the muscle molecular motor with the
actin-
myosin ATPase inhibitor, which blocks
hydrolysis of ATP, then reduces release of bio-energy for the
muscle contraction.Our studies
in vitro and
in vivo have demonstrated that BDM, an
ATPase inhibitor, thereby, its analogues, derivatives, and other chemicals possessing similar effect on
ATPase may be used as bio-energy muscle relaxants (general muscle relaxants).